z-logo
open-access-imgOpen Access
Clinical application and efficacy of negative pressure wound therapy with instillation and dwell time ( NPWTi ‐d): A systematic review and meta‐analysis
Author(s) -
Kanapathy Muholan,
Mantelakis Angelos,
Khan Natasha,
Younis Ibby,
Mosahebi Afshin
Publication year - 2020
Publication title -
international wound journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.867
H-Index - 63
eISSN - 1742-481X
pISSN - 1742-4801
DOI - 10.1111/iwj.13487
Subject(s) - medicine , adverse effect , surgery , saline , meta analysis , wound healing , dwell time , negative pressure wound therapy , anesthesia , clinical psychology , alternative medicine , pathology
This study evaluates the current clinical evidence of Negative Pressure Wound Therapy with Instillation and dwell time (NPWTi‐d) to establish its clinical application and efficacy. MEDLINE, EMBASE, and CENTRAL databases were searched from 1946 to July 2019 for studies reporting clinical outcomes on wounds treated with NPWTi‐d. The primary outcome was proportion of wounds with complete healing. The secondary outcomes were mean time for healing, NPWTi‐d settings, cost, length of stay, and adverse events. Thirteen articles were included with a total of 624 wounds in 542 patients involving wounds of various aetiology. The pooled proportion of wound that achieved complete healing was 93.65% (95%CI: 84.02‐99.04). Normal saline was the most commonly used instillation solution with the mean dwell time of 14.23 minutes (95%CI: 10.88‐17.59) and instillation cycle every 4.17 ± 2.32 hourly. The mean therapy duration was 10.69 days (95%CI: 10.46‐10.91) with daily cost of $194.80. The mean hospital stay was 18.1 days (95%CI: 17.20‐19.00). There were no severe adverse effects reported. NPWTi‐d is an adjuntive therapy to aid complete healing of the vast majority of wounds. However, the current data are limited by the lack of level 1 evidence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here